<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614756</url>
  </required_header>
  <id_info>
    <org_study_id>IM134-002</org_study_id>
    <secondary_id>2012-001865-34</secondary_id>
    <nct_id>NCT01614756</nct_id>
  </id_info>
  <brief_title>A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis</brief_title>
  <official_title>A Two-Part, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of Subcutaneous and Intravenous Administration of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody; BMS-981164) in Healthy Subjects and Adult Subjects With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine safety and tolerability of IL-31 mAB
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy Volunteers not acceptable for &quot;Part 2&quot; (Adult subjects with Atopic Dermatitis)

      Enrollment: (both Part 1 and Part 2) Part 2 will consist of up to 42 patients with atopic
      dermatitis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For both Part 1 and Part 2, the primary endpoint will be based on incident adverse event reports, vital sign measurements, physical (including injection site) examinations, electrocardiograms (ECGs), medical history, and clinical laboratory tests</measure>
    <time_frame>Up to 16 weeks after single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Maximum observed serum concentration (Cmax) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time of maximum observed serum concentration (Tmax) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area under the serum concentration-time curve from zero to time of the last quantifiable concentration [AUC(0-T)] of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Terminal serum half-life (T-HALF) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent volume of distribution at steady state (Vss/F) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Volume of distribution at steady state (Vss) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent total body clearance (CLT/F) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total body clearance (CLT) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Absolute bioavailability (F) of BMS-981164 will be derived from serum concentration versus time</measure>
    <time_frame>13 timepoints upto 16 weeks after single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of subjects with one or more positive post-treatment anti-drug antibodies (ADA) assessments</measure>
    <time_frame>Up to 16 weeks after single dose</time_frame>
    <description>The Immunogenicity of BMS-981164 will be assessed by this ADA assessments</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Healthy Subjects and Atopic Dermatitis Subjects</condition>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 0.1 mg/kg solution subcutaneously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 0.01 mg/kg solution subcutaneously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 0.03 mg/kg solution subcutaneously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 0.06 mg/kg solution subcutaneously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 0.1 mg/kg solution subcutaneously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 0.3 mg/kg solution subcutaneously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 1 mg/kg solution subcutaneously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 1 mg/kg solution intravenously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 3 mg/kg solution intravenously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1
Single dose of BMS-981164 10.0 mg/kg solution intravenously
OR
Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2
BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose
OR
Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2
BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose
OR
Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2
BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose
OR
Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2
BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and &gt;1.0mg/kg, once, single dose
OR
Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-981164</intervention_name>
    <arm_group_label>Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 1)</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 2)</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 3)</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 4)</arm_group_label>
    <other_name>IL-31 mAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo matching with BMS-981164</intervention_name>
    <arm_group_label>Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 1)</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 2)</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 3)</arm_group_label>
    <arm_group_label>Dose Escalation- BMS-981164 or Placebo (dose group 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Part 1: Healthy subjects

          -  Part 2: Adult subjects with:

               1. Atopic dermatitis severity as assessed by Physician Global Assessment rating of 3
                  or higher (i.e., moderate or greater) on a scale of 0 to 5

               2. Pruritus severity of at least 7 of 10 on a visual analog scale

        Exclusion Criteria:

          -  Receipt of systemic immunosuppressants, other than biological agents, or topical
             calcineurin inhibitors (tacrolimus or pimecrolimus) within 4 weeks prior to study drug
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M15 6SH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

